DeNovaMed Open to a Prompt Sale
As it moves toward its Phase I regulatory trials, Halifax-based biotech DeNovaMed is showing admirable flexibility in its financing options.
The company, which is developing compounds that can battle “superbugs”, sprang to prominence in January when it won Innovacorp’s I-3 competition for innovation. The four co-founders have been working on the project for five years and believe they have isolated compounds that can battle these viruses, which are resistant to antibiotics currently available on the market.
During its presentation at the I-3 competition, the team made the potential of